Allergy Therapeutics (LON:AGY) Reaches New 12-Month High at $27.00

Shares of Allergy Therapeutics plc (LON:AGY) reached a new 52-week high during trading on Thursday . The stock traded as high as GBX 27 ($0.35) and last traded at GBX 27 ($0.35), with a volume of 169023 shares changing hands. The stock had previously closed at GBX 26 ($0.34).

The firm’s 50-day moving average is GBX 24.54. The firm has a market cap of £173.28 million and a price-to-earnings ratio of 26.00. The company has a quick ratio of 3.61, a current ratio of 4.23 and a debt-to-equity ratio of 20.42.

Allergy Therapeutics Company Profile (LON:AGY)

Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics.

Read More: Management Fee

Receive News & Ratings for Allergy Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergy Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.